Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for depressive and negative symptoms in schizophrenia
2024-519097-39-01Phase 3Authorised
- Sponsor
- Medical University of Vienna
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esketamine in schizophrenia and schizoaffective disorder (2 arms), sponsored by Medical University of Vienna. Primary endpoints: Change in Brief Negative Symptom Scale (BNSS) score and Change in Montgomery-Asberg Depression Rating Scale (MADRS) score. Planned start Feb 2025; status: authorised.
02
Drugs
esketamine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2024-519097-39-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519097-39-01.